Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

EGFR mutations in lung cancer: from tissue testing to liquid biopsy.

Future oncology (London, England) - 1 Jan 2015

Fenizia Francesca, De Luca Antonella, Pasquale Raffaella, Sacco Alessandra, Forgione Laura, Lambiase Matilde, Iannaccone Alessia, Chicchinelli Nicoletta, Franco Renato, Rossi Antonio, Morabito Alessandro, Rocco Gaetano, Piccirillo Maria Carmela, Normanno Nicola

Abstract excerpt

ABSTRACT The presence of EGFR mutations predicts the sensitivity to EGF receptor (EGFR)-tyrosine kinase inhibitors in a molecularly defined subset of non-small-cell lung carcinoma (NSCLC) patients. For this reason, EGFR testing of NSCLC is required to provide personalized treatment options and better outcomes for NSCLC patients. As surgery specimens are not available in the majority of NSCLC, other currently...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biopsy
Share to DNA, Neoplasm

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Neoplasm

Share to Erlotinib Hydrochloride

Share to Gefitinib

Share to Genotyping Techniques

Share to Precision Medicine

Share to Quinazolines

Source

Identifiers

PMID: 26043215
DOI: 10.2217/fon.15.23

Genes

EGFR
EGF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

EGFR mutations in lung cancer: from tissue testing to liquid biopsy.PMID 26043215Read ↗

The Emergent Landscape of Detecting EGFR Mutations Using Circulating Tumor DNA in Lung Cancer.Semantic proximity Read ↗

Are liquid biopsies a surrogate for tissue EGFR testing?Semantic proximity Read ↗

A liquid biopsy in primary lung cancer.Semantic proximity Read ↗

The Emerging Role of "Liquid Biopsies," Circulating Tumor Cells, and Circulating Cell-Free Tumor DNA in Lung Cancer Diagnosis and Identification of Resistance Mutations.Semantic proximity Read ↗

Guide to detecting epidermal growth factor receptor (EGFR) mutations in ctDNA of patients with advanced non-small-cell lung cancer.Semantic proximity Read ↗

ctDNA for the Evaluation and Management of EGFR-Mutant Non-Small Cell Lung CancerSemantic proximity Read ↗

Liquid biopsy genotyping in lung cancer: ready for clinical utility?Semantic proximity Read ↗

Next generation sequencing techniques in liquid biopsy: focus on non-small cell lung cancer patientsSemantic proximity Read ↗

Update on molecular pathology and role of liquid biopsy in nonsmall cell lung cancer.Semantic proximity Read ↗

Emerging platforms using liquid biopsy to detect EGFR mutations in lung cancer.Semantic proximity Read ↗

Liquid biopsy tracking of lung tumor evolutions over timeSemantic proximity Read ↗

Update on EGFR Mutational Testing and the Potential of Noninvasive Liquid Biopsy in Non-Small-cell Lung Cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.